Now showing items 1-3 of 3

    • Alzheimer's Disease-Related Polymorphisms in Shunt-Responsive Idiopathic Normal Pressure Hydrocephalus 

      Huovinen J; Helisalmi S; Paananen J; Laiterä T; Kojoukhova M; Sutela A; Vanninen R; Laitinen M; Rauramaa T; Koivisto AM; Remes AM; Soininen H; Kurki M; Haapasalo A; Jääskeläinen JE; Hiltunen M; Leinonen V (IOS PressAlankomaat, 2017)
      Background: Idiopathic normal pressure hydrocephalus (iNPH) is a late onset, surgically treated progressive brain disease caused by impaired cerebrospinal fluid dynamics and subsequent ventriculomegaly. Comorbid Alzheimer’s ...
    • Common data elements and data management: Remedy to cure underpowered preclinical studies 

      Lapinlampi N; Melin E; Aronica E; Bankstahl JP; Becker A; Bernard C; Gorter JA; Gröhn O; Lipsanen A; Lukasiuk K; Löscher W; Paananen J; Ravizza T; Roncon P; Simonato M; Vezzani A; Kokaia M; Pitkänen A (Elsevier BV, 2016)
      Lack of translation of data obtained in preclinical trials to clinic has kindled researchers to develop new methodologies to increase the power and reproducibility of preclinical studies. One approach relates to harmonization ...
    • Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study 

      de Mello VD; Paananen J; Lindstrom J; Lankinen MA; Shi L; Kuusisto J; Pihlajamaki J; Auriola S; Lehtonen M; Rolandsson O; Bergdahl IA; Nordin E; Ilanne-Parikka P; Keinänen-Kiukaanniemi S; Landberg R; Eriksson JG; Tuomilehto J; Hanhineva K; Uusitupa M (Springer Nature, 2017)
      Wide-scale profiling technologies including metabolomics broaden the possibility of novel discoveries related to the pathogenesis of type 2 diabetes (T2D). By applying non-targeted metabolomics approach, we investigated ...